April 24, 2014 — The global biopsy devices market value will increase at a modest rate over the coming years, climbing from $506.4 million in 2013 to $602.4 million by 2019, at a compound annual growth rate (CAGR) of 2.93%, forecasts research and consulting firm GlobalData.

According to the company’s latest report, MediPoint: Biopsy Devices - Global Analysis and Market Forecasts, the biopsy devices market in emerging economies, such as China, India and Brazil, will increase at much higher CAGRS than the global rate, reaching shares of 24%, 10% and 6% by 2019, respectively.

Despite the modest global growth, several barriers are dampening the potential adoption of biopsy devices within a number of markets. Notably in the United States, reimbursement for image-guided breast biopsies has undergone drastic cuts, which GlobalData expects will have a significant effect on the adoption of more expensive vacuum-assisted biopsy (VAB) devices.

Joseph Gregory, GlobalData’s analyst covering surgical devices, said: “Additionally, routine screening for prostate cancer and breast cancer has come under scrutiny, as sophisticated clinical trials reveal that these interventions have a minimal impact on the cancer related mortality. This is a long-term setback for the adoption of biopsy devices in diagnosing these cancers, given that these criticisms could curb adoption of routine screening.”

While these challenges are likely to affect the biopsy devices market, GlobalData believes that current and future players can still position themselves to obtain a competitive advantage.

“The major European countries have general mass-screening programs for breast cancer detection and will be increasing their adoption of VAB devices over the forecast period. Additionally, the emerging economies are increasing their access to healthcare resources and showing a preference for more expensive core needle biopsy devices over fine needle aspiration devices,” Gregory concluded.

For more information: www.globaldata.com/QuotingGlobalData.aspx

Related Content

News | Breast Biopsy Systems

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around ...

Time July 07, 2021
arrow
News | Breast Imaging

January 4, 2021 — Hologic, Inc. announced it has completed the acquisition of SOMATEX Medical Technologies GmbH, a ...

Time January 04, 2021
arrow
News | Brachytherapy Systems

October 26, 2020 — iCAD, Inc. announced the Company will showcase the expanded platform for the Xoft Axxent Electronic ...

Time October 26, 2020
arrow
News | Brachytherapy Systems, Women's Healthcare

September 8, 2020 — Advanced Radiation Therapy has completed the installation of the AccuBoost Digital platform at the ...

Time September 08, 2020
arrow
News | Breast Biopsy Systems

August 28, 2020 — Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health ...

Time August 28, 2020
arrow
News | Breast Imaging

November 26, 2019 — Unifi Workspace, a new comprehensive breast diagnostic reading solution from Hologic, will launch at ...

Time November 26, 2019
arrow
Feature | Breast Biopsy Systems | By Harriet Borofsky, M.D.

The current body of research supporting digital breast tomosynthesis (DBT or 3-D mammography) is now overwhelming, with ...

Time October 17, 2019
arrow
News | Prostate Cancer

According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their lifetime. It’s both the second most common cancer and second most common cause of cancer death in American men. Early detection is critical and can increase a man’s chances of survival.

Time August 20, 2019
arrow
Technology | Breast Biopsy Systems

Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its Tomosynthesis Biopsy option for the Aspire Cristalle mammography system. This new option uses tomosynthesis guidance to calculate 3-D coordinates of a suspicious lesion in the breast, in addition to the traditional stereotactic method. This allows radiologists to accurately complete biopsy of suspicious areas to conduct a pathological examination and inform the diagnosis and care plan. Clinicians will now be able to enhance diagnostic care for patients by using Tomosynthesis Biopsy to target a lesion previously undetectable on images from full field digital mammography (FFDM) alone.

Time July 24, 2019
arrow
Technology | Breast Biopsy Systems

Hologic Inc. announced global commercial availability of the Trident HD specimen radiography system. The next-generation solution delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.

Time April 26, 2019
arrow
Subscribe Now